Skip to main content
Evidence Snapshot

Dihydrofolate reductase

CHEMBL6065 SINGLE PROTEIN Mycobacterium tuberculosis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6065
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dihydrofolate reductase as ChEMBL target CHEMBL6065, mapped to UniProt P9WNX1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dihydrofolate reductase
SINGLE PROTEIN · Mycobacterium tuberculosis
As of 2026-09-14
ChEMBL target ID
CHEMBL6065
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P9WNX1
Dihydrofolate reductase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dihydrofolate reductase matters

As of 2026-09-14

Dihydrofolate reductase is reviewed as Dihydrofolate reductase (UniProt P9WNX1); Dihydrofolate reductase shows approved-linked disease relevance led by tuberculosis. 4 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 73 compounds, and 22 assays, with lead potency reaching pChEMBL 9.0.

Disease context
tuberculosis

Dihydrofolate reductase shows approved-linked disease relevance led by tuberculosis. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include AMINOSALICYLATE SODIUM, AMINOSALICYLIC ACID.

Start review with tuberculosis because it currently carries approved-linked support. Linked drugs include AMINOSALICYLATE SODIUM, AMINOSALICYLIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 73 compounds, and 22 assays for this target. The dominant activity type is IC50. CHEMBL5279457 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL5279457 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dihydrofolate reductase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P9WNX1, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why tuberculosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

73
Total Compounds
22
Total Assays
3
Approved Drugs
IC50: 53.0, KI: 1.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5279457
 9.0 IC50 —
No preferred name
CHEMBL64
 9.0 Ki Approved
No preferred name
CHEMBL1904209
 8.2 IC50 —
No preferred name
CHEMBL526013
 8.1 IC50 —
No preferred name
CHEMBL34259
 8.1 IC50 Approved

Approved Drugs

Structure Compound First Approval
METHOTREXATE
CHEMBL34259
 1953
ISONIAZID
CHEMBL64
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6065